SEC Tracker
Get the app

Dyne Therapeutics DYN

Atlas Venture Opportunity Fund I (Shareholder) plans to sell 100,000 DYN shares, about $2.2M

Form
144
Filed
Importance
Routine
Document
Form 144
  1. Approximate sale date: Feb 23, 2024
  2. Broker: Merrill
  3. Shares acquired by: Private Placement
  4. 10b5-1 plan adopted: Jan 10, 2024

All of Atlas Venture Opportunity Fund I's insider filings, holdings and planned sales

Form 4s that likely executed this notice (SEC Tracker's match by person, company, dates and shares):

  • Sold 64,783 shares at $23.98 on Feb 26, 2024 · Form 4
  • Sold 9,603 shares at $23.98 on Feb 26, 2024 · Form 4
  • Sold 11,736 shares at $23.59 on Feb 26, 2024 · Form 4
  • Sold 3,821 shares at $24.68 on Feb 27, 2024 · Form 4
  • Sold 2,430 shares at $25.25 on Feb 28, 2024 · Form 4
  • Sold 210 shares at $25.25 on Feb 28, 2024 · Form 4

Written from the Form 144 on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when Dyne Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Akebia Therapeutics AKBA public float $946M, Jun 30, 2025
  2. Viridian Therapeutics VRDN public float $943M, Jun 30, 2025
  3. Collegium Pharmaceutical COLL public float $926M, Jun 30, 2025
  4. Neogen NEOG public float $972M, Nov 30, 2025
  5. Ardelyx ARDX public float $924M, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.